Phase 2a Trial of Riluzole for Cancer-Related Cognitive Impairment Initiated
A phase 2a pilot trial is underway to assess riluzole's effects on BDNF levels in cancer survivors with cognitive impairment.
Asset / Drug
Drug and asset intelligence for Riluzole with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.